ビンダケルの世界市場レポート 2025年

ビンダケル市場規模は、今後数年で急成長が見込まれます。2029年にはCAGR17.1％で36億7,000万米ドルに成長します。予測期間における成長の原動力は、研究開発投資の増加、精密医療の採用拡大、医師の精通度の向上、診断ツールの利用可能性の拡大、政府のイニシアティブの拡大です。主要動向としては、遠隔医療施設の拡大、戦略的提携、遺伝子検査の進歩、デジタルヘルスツールの統合、個別化医療の台頭などが挙げられます。

研究開発への投資の増加は、今後数年間のビンダケル市場の成長を促進すると予想されます。研究開発には、体系的な調査や実験を通じて、製品やサービス、プロセスを革新・強化することが含まれます。研究開発投資の増加は、神経疾患の有病率の増加、医療技術の進歩、革新的な治療法に対する認識と需要の高まり、政府と民間部門の両方からの重要な資金提供イニシアティブに起因しています。研究開発への投資は、治療法の開発と最適化を加速し、その有効性と患者へのアクセシビリティを高めています。また、ビンダケルの進歩を促進し、有効性、入手可能性、適応拡大の可能性を向上させています。例えば、2024年7月、英国の政府機関であるDepartment of Health and Social Careは、英国の企業セクタが2022年に約111億米ドル相当の医薬品の研究開発を行い、これは国の国内総生産の0.36％に相当すると報告しました。その結果、研究開発への投資の増加がビンダケル市場の拡大に拍車をかけています。

また、精密医療の採用拡大もビンダケル市場の拡大に寄与すると期待されています。個別化医療とは、遺伝的要因、環境要因、ライフスタイル要因に基づいて、個々の患者に合わせた治療を行うことです。個別化医療の採用が増加している背景には、ゲノム研究の進歩、治療効果の向上、慢性疾患の有病率の上昇があります。このアプローチは、トランスサイレチンアミロイドーシス（ATTR）のより正確な診断と的を絞った治療を可能にし、最も恩恵を受ける患者に確実に薬剤を届けることで、ビンダケルに利益をもたらします。治療効果を高め、患者の転帰を改善することで、個別化医療の採用が増加し、市場の成長を支え、ビンダケルのような専門的な治療法の需要を高めています。例えば、2024年2月、米国の非営利団体である個別化医療連合（Personalized Medicine Coalition）は、米国食品医薬品局（FDA）が2023年に希少疾患患者向けに16の新規個別化療法を承認し、2022年の6承認から大幅に増加したと報告しました。その結果、精密医療の採用が増加しており、ビンダケル市場の成長を牽引しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場-マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界のビンダケル PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のビンダケル市場：成長率分析
• 世界のビンダケル市場の実績：規模と成長、2019～2024年
• 世界のビンダケル市場の予測：規模と成長、2024～2029年、2034年
• 世界のビンダケル総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のビンダケル市場：製品タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• ビンダケル（タファミジス20mg）
• ビンダマックス（タファミジス61mg）
• 世界のビンダケル市場：疾患タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 家族性アミロイド多発ニューロパチー（FAP）
• 野生型または遺伝性トランスサイレチン介在性アミロイドーシス心筋症（ATTR-CM）
• 世界のビンダケル市場：流通チャネル別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院薬局
• オンライン薬局
• 小売薬局
• 世界のビンダケル市場、ビンダケル（タファミジス20mg）のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 経口錠
• 経口溶液
• 世界のビンダケル市場、ビンダマックス（タファミジス61mg）のサブセグメンテーション、タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• 経口カプセル
• 経口懸濁液

第7章 地域別・国別分析

• 世界のビンダケル市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界のビンダケル市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• ビンダケル市場：競合情勢
• ビンダケル市場：企業プロファイル
  • Pfizer Inc.

第31章 世界の市場競合ベンチマーキングとダッシュボード

第32章 主要な合併と買収

第33章 最近の市場動向

第34章 市場の潜在力が高い国、戦略

• ビンダケル市場、2029年：新たな機会を提供する国
• ビンダケル市場、2029年：新たな機会を提供するセグメント
• ビンダケル市場、2029年：成長戦略
  • 市場動向による戦略
  • 競合の戦略

第35章 付録

Vyndaqel, also known as tafamidis, is a medication used to treat transthyretin amyloid cardiomyopathy (ATTR-CM), a heart condition caused by the accumulation of misfolded transthyretin proteins. It works by stabilizing the transthyretin protein, preventing its misfolding and buildup in the heart. Vyndaqel helps reduce cardiovascular-related deaths and hospitalizations while improving the quality of life for patients with this progressive and potentially fatal disease.

The primary product types of Vyndaqel include Vyndaqel (tafamidis 20 mg) and Vyndamax (tafamidis 61 mg). Vyndaqel (tafamidis 20 mg) is a transthyretin stabilizer used to treat transthyretin amyloid polyneuropathy (ATTR-PN) by slowing disease progression. It is indicated for familial amyloid polyneuropathy (FAP) and wild-type or hereditary transthyretin-mediated amyloidosis cardiomyopathy (ATTR-CM). Vyndaqel is distributed through hospital pharmacies, online pharmacies, and retail pharmacies.

The vyndaqel market research report is one of a series of new reports from The Business Research Company that provides vyndaqel market statistics, including vyndaqel industry global market size, regional shares, competitors with a vyndaqel market share, detailed vyndaqel market segments, market trends and opportunities, and any further data you may need to thrive in the vyndaqel industry. This vyndaqel market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The vyndaqel market size has grown rapidly in recent years. It will grow from $1.62 billion in 2024 to $1.91 billion in 2025 at a compound annual growth rate (CAGR) of 18.1%. The growth during the historic period can be attributed to increasing awareness of transthyretin amyloidosis, a rising prevalence of transthyretin-mediated amyloidosis cardiomyopathy, a greater focus on rare diseases, growing government support, an increase in clinical trials, and a growing geriatric population.

The vyndaqel market size is expected to see rapid growth in the next few years. It will grow to $3.67 billion in 2029 at a compound annual growth rate (CAGR) of 17.1%. The projected growth in the forecast period is driven by increasing investment in research and development, the growing adoption of precision medicine, rising physician familiarity, greater availability of diagnostic tools, and expanding government initiatives. Key trends include the expansion of telemedicine facilities, strategic collaborations, advancements in genetic testing, the integration of digital health tools, and the rise of personalized medicine.

The increasing investment in research and development is expected to drive the growth of the Vyndaqel market in the coming years. Research and development involve innovating and enhancing products, services, or processes through systematic investigation and experimentation. The rise in R&D investment is attributed to the increasing prevalence of neurological disorders, advancements in medical technology, growing awareness and demand for innovative treatments, and significant funding initiatives from both government and private sectors. Investment in research and development accelerates the development and optimization of therapies, enhancing their efficacy and accessibility for patients. It fosters advancements in Vyndaqel, improving its effectiveness, availability, and potential for expanded indications. For example, in July 2024, the Department of Health and Social Care, a UK-based government department, reported that the business enterprise sector in the UK conducted pharmaceutical research and development worth approximately $11.1 billion in 2022, representing 0.36% of the nation's gross domestic product. As a result, increasing investment in research and development is fueling the expansion of the Vyndaqel market.

The growing adoption of precision medicine is also expected to contribute to the expansion of the Vyndaqel market. Personalized medicine involves tailoring medical treatments to individual patients based on their genetic, environmental, and lifestyle factors. The increasing adoption of personalized medicine is driven by advancements in genomic research, improved treatment efficacy, and the rising prevalence of chronic diseases. This approach benefits Vyndaqel by enabling more precise diagnosis and targeted treatment for transthyretin amyloidosis (ATTR), ensuring that the drug reaches patients who will benefit the most. By enhancing treatment efficacy and improving patient outcomes, the rising adoption of personalized medicine supports market growth and increases the demand for specialized therapies such as Vyndaqel. For instance, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that the US Food and Drug Administration (FDA) approved 16 novel personalized therapies for patients with rare diseases in 2023, a significant increase from six approvals in 2022. As a result, the increasing adoption of precision medicine is driving the growth of the Vyndaqel market.

Major companies in the Vyndaqel market are expanding their production facilities to manufacture active pharmaceutical ingredients (APIs). Facility expansion involves increasing physical infrastructure, production capacity, or operational capabilities to accommodate growth, enhance efficiency, and meet rising demand. For example, in July 2024, Pfizer Inc., a US-based pharmaceutical company that manufactures Vyndaqel, inaugurated a $1 billion plant in Singapore's Tuas Biomedical Park. This new 429,000 sq ft facility will produce active pharmaceutical ingredients for Pfizer's cancer, pain, and antibiotic medications. As an extension of Pfizer's existing site, which has been operational for 20 years, the new facility is expected to create 250 highly skilled jobs. The plant has also been awarded a Green Mark Gold certification for its environmental sustainability efforts and aligns with Pfizer's commitment to achieving net-zero emissions by 2040.

The key player in the vyndaqel market is Pfizer Inc.

North America was the largest region in the vyndaqel market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in vyndaqel report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the vyndaqel market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The vyndaqel market consists of sales of cardiovascular medications, neuropathy medications, anticoagulants and diuretics. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Vyndaqel Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on vyndaqel market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for vyndaqel ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The vyndaqel market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product Type: Vyndaqel (Tafamidis 20 mg); Vyndamax (Tafamidis 61 mg)
• 2) By Disease Type: Familial Amyloid Polyneuropathy (FAP); Wild-Type Or Hereditary Transthyretin-Mediated Amyloidosis Cardiomyopathy (ATTR-CM)
• 3) By Distribution Channel: Hospital Pharmacies; Online Pharmacies; Retail Pharmacies
• Subsegments:
• 1) By Vyndaqel (Tafamidis 20 mg): Oral Tablets; Oral Solution
• 2) By Vyndamax (Tafamidis 61 mg): Oral Capsules; Oral Suspension
• Companies Mentioned: Pfizer Inc.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Vyndaqel Market Characteristics

3. Vyndaqel Market Trends And Strategies

4. Vyndaqel Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Vyndaqel Growth Analysis And Strategic Analysis Framework

• 5.1. Global Vyndaqel PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Vyndaqel Market Growth Rate Analysis
• 5.4. Global Vyndaqel Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Vyndaqel Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Vyndaqel Total Addressable Market (TAM)

6. Vyndaqel Market Segmentation

• 6.1. Global Vyndaqel Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Vyndaqel (Tafamidis 20 mg)
• Vyndamax (Tafamidis 61 mg)
• 6.2. Global Vyndaqel Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Familial Amyloid Polyneuropathy (FAP)
• Wild-Type Or Hereditary Transthyretin-Mediated Amyloidosis Cardiomyopathy (ATTR-CM)
• 6.3. Global Vyndaqel Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Online Pharmacies
• Retail Pharmacies
• 6.4. Global Vyndaqel Market, Sub-Segmentation Of Vyndaqel (Tafamidis 20 mg), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral Tablets
• Oral Solution
• 6.5. Global Vyndaqel Market, Sub-Segmentation Of Vyndamax (Tafamidis 61 mg), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral Capsules
• Oral Suspension

7. Vyndaqel Market Regional And Country Analysis

• 7.1. Global Vyndaqel Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Vyndaqel Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Vyndaqel Market

• 8.1. Asia-Pacific Vyndaqel Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Vyndaqel Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Vyndaqel Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Vyndaqel Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Vyndaqel Market

• 9.1. China Vyndaqel Market Overview
• 9.2. China Vyndaqel Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Vyndaqel Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Vyndaqel Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Vyndaqel Market

• 10.1. India Vyndaqel Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Vyndaqel Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Vyndaqel Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Vyndaqel Market

• 11.1. Japan Vyndaqel Market Overview
• 11.2. Japan Vyndaqel Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Vyndaqel Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Vyndaqel Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Vyndaqel Market

• 12.1. Australia Vyndaqel Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Vyndaqel Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Vyndaqel Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Vyndaqel Market

• 13.1. Indonesia Vyndaqel Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Vyndaqel Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Vyndaqel Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Vyndaqel Market

• 14.1. South Korea Vyndaqel Market Overview
• 14.2. South Korea Vyndaqel Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Vyndaqel Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Vyndaqel Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Vyndaqel Market

• 15.1. Western Europe Vyndaqel Market Overview
• 15.2. Western Europe Vyndaqel Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Vyndaqel Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Vyndaqel Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Vyndaqel Market

• 16.1. UK Vyndaqel Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Vyndaqel Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Vyndaqel Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Vyndaqel Market

• 17.1. Germany Vyndaqel Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Vyndaqel Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Vyndaqel Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Vyndaqel Market

• 18.1. France Vyndaqel Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Vyndaqel Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Vyndaqel Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Vyndaqel Market

• 19.1. Italy Vyndaqel Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Vyndaqel Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Vyndaqel Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Vyndaqel Market

• 20.1. Spain Vyndaqel Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Vyndaqel Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Vyndaqel Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Vyndaqel Market

• 21.1. Eastern Europe Vyndaqel Market Overview
• 21.2. Eastern Europe Vyndaqel Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Vyndaqel Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Vyndaqel Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Vyndaqel Market

• 22.1. Russia Vyndaqel Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Vyndaqel Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Vyndaqel Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Vyndaqel Market

• 23.1. North America Vyndaqel Market Overview
• 23.2. North America Vyndaqel Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Vyndaqel Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Vyndaqel Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Vyndaqel Market

• 24.1. USA Vyndaqel Market Overview
• 24.2. USA Vyndaqel Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Vyndaqel Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Vyndaqel Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Vyndaqel Market

• 25.1. Canada Vyndaqel Market Overview
• 25.2. Canada Vyndaqel Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Vyndaqel Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Vyndaqel Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Vyndaqel Market

• 26.1. South America Vyndaqel Market Overview
• 26.2. South America Vyndaqel Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Vyndaqel Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Vyndaqel Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Vyndaqel Market

• 27.1. Brazil Vyndaqel Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Vyndaqel Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Vyndaqel Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Vyndaqel Market

• 28.1. Middle East Vyndaqel Market Overview
• 28.2. Middle East Vyndaqel Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Vyndaqel Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Vyndaqel Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Vyndaqel Market

• 29.1. Africa Vyndaqel Market Overview
• 29.2. Africa Vyndaqel Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Vyndaqel Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Vyndaqel Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Vyndaqel Market Competitive Landscape And Company Profiles

• 30.1. Vyndaqel Market Competitive Landscape
• 30.2. Vyndaqel Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Global Vyndaqel Market Competitive Benchmarking And Dashboard

32. Key Mergers And Acquisitions In The Vyndaqel Market

33. Recent Developments In The Vyndaqel Market

34. Vyndaqel Market High Potential Countries, Segments and Strategies

• 34.1 Vyndaqel Market In 2029 - Countries Offering Most New Opportunities
• 34.2 Vyndaqel Market In 2029 - Segments Offering Most New Opportunities
• 34.3 Vyndaqel Market In 2029 - Growth Strategies
  • 34.3.1 Market Trend Based Strategies
  • 34.3.2 Competitor Strategies

35. Appendix

• 35.1. Abbreviations
• 35.2. Currencies
• 35.3. Historic And Forecast Inflation Rates
• 35.4. Research Inquiries
• 35.5. The Business Research Company
• 35.6. Copyright And Disclaimer